L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 15:23:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      14 TO ITERATE

100.0% PROCESSED       14 ITERATIONS                          3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:             56 TO       504
PROJECTED ANSWERS:                 3 TO       163

L2             3 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 15:23:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     300 TO ITERATE

100.0% PROCESSED      300 ITERATIONS                         20 ANSWERS
SEARCH TIME: 00.00.01

L3            20 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             148.15     148.36

FILE 'CAPLUS' ENTERED AT 15:23:44 ON 09 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is

FILE COVERS 1907 - 9 May 2003 VOL 138 ISS 20
FILE LAST UPDATED: 8 May 2003 (20030508/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 2 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:137218 CAPLUS
DOCUMENT NUMBER: 134:193607
TITLE: Preparation of phenanthrolin-7-one derivatives and their therapeutic uses as antitumoral medicines
INVENTOR(S): Delfourne, Evelyne; Darro, Francis; Bastide, Jean; Kiss, Robert; Frydman, Armand
PATENT ASSIGNEE(S): Laboratoire L. Lafon, Fr.
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012632	A2	20010222	WO 2000-FR2313	20000811
WO 2001012632	A3	20010719		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2797446	A1	20010216	FR 1999-10493	19990813
FR 2797446	B1	20011102		
BR 2000013239	A	20020423	BR 2000-13239	20000811
EP 1202993	A2	20020508	EP 2000-958679	20000811
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NO 2002000669	A	20020415	NO 2002-669	20020211

PRIORITY APPLN. INFO.: FR 1999-10493 A 19990813
WO 2000-FR2313 W 20000811

OTHER SOURCE(S): CASREACT 134:193607; MARPAT 134:193607

GI



I



II

AB The invention concerns a pharmaceutical compn. comprising an efficient amt. of a compd. selected among the compds. I [R1, R2, R3, R4, R5 = H, halogen, C1-6-alkyl, OH, CHO, OR8, CO2H, CN, CO2R8, CONHR8, CONR8R9, NH2, NHR8, N(R8)2, NHCH2CH2NMe2, NHCH2CH2Cl, NHCOR8, morpholino, NO2, SO3H, CH2N(CO2R8)CH2CO2R9, CH2N(CO2R8)CH2Ar; R6 = H, halogen, C1-6-alkyl, (CH2)nR10, ; R7 = H, C1-6-alkyl, Ph-C1-4-alkyl, NR15R16; R8, R9 = C1-6-alkyl, Ph-C1-4-alkyl; R10 = halogen, OH, C1-6-alkoxy, OC(:O)-C1-6-alkyl, CN, CO2Et, COR11; R11 = Ph-C1-4-alkyl, NR12R13; R12 , R13 = H, C1-6-alkyl, Ph-C1-4-alkyl, (CH2)nR14; R14 = halogen, C1-6-alkoxy, NMe2; R15, R16 = H, C1-6-alkyl, Ph-C1-4-alkyl, (CH2)nR17; R17 = H, halogen, OH, C1-6-alkoxy; Ar = C6-14-aryl; n = 1 - 6] and II or their pharmaceutically acceptable salts. Thus, I [R1 = R2 = R3 = R4 = R5 = R6 = R7 = H (CRL8293)] and II [R1 = R2 = R3 = R4 = R5 = R6 = R7 = H (CRL8294)] were prepd. from quinoline-5,8-dione via Diels-Alder with crotonaldehyde dimethylhydrazone followed by cyclocondensation of the resulting quinone III with Me2NCMe(OEt)2. I (R1 = R2 = R3 = R4 = R5 = R6 = R7 = H) and II (R1 = R2 = R3 = R4 = R5 = R6 = R7 = H) have interesting cytotoxic properties [DMT = 10 mg/Kg (DMT = max. tolerable dose); -33% and -36%, resp. tumor surface diminution {murin mammary carcinoma (MXT-HI)}; -45% and -64% , resp. tumor surface diminution [{murin mammary adenocarcinoma (MXT-HS)}]; and, for II, T/C = 136% (lymphoma L1210)] leading to a therapeutic use as antitumoral medicines.

IT **266306-76-7P**, CRL 8294 **327184-13-4P**, CRL 8364
327184-14-5P **327184-15-6P**, CRL 8401 **327184-16-7P**
, CRL 8440 **327184-17-8P**, CRL 8479 **327184-18-9P**
327184-19-0P, CRL 8485 **327184-20-3P** **327184-21-4P**
, 3-(Acetoxymethyl)-9-methoxy-7H-pyrido[4,3,2-de][1,10]phenanthrolin-7-one
327184-22-5P, CRL 8830 **327184-33-8P**, CRL 8367
327184-35-0P, CRL 8388 **327184-37-2P**, CRL 8441
327184-39-4P, CRL 8482 **327184-41-8P**, CRL 8483
327184-43-0P, CRL 8486 **327184-45-2P**, CRL 8487
327184-47-4P, CRL 8480 **327184-49-6P**, CRL 8481
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenanthrolin-7-one derivs. and their therapeutic uses as antitumoral medicines)

RN 266306-76-7 CAPLUS

CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one (9CI) (CA INDEX NAME)



RN 327184-13-4 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 11-methoxy- (9CI) (CA INDEX NAME)



RN 327184-14-5 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 11-chloro- (9CI) (CA INDEX NAME)



RN 327184-15-6 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 4-methoxy- (9CI) (CA INDEX NAME)



RN 327184-16-7 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 4,11-dimethoxy- (9CI) (CA INDEX NAME)



RN 327184-17-8 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 4,9-dimethoxy- (9CI) (CA INDEX NAME)



RN 327184-18-9 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 9-methoxy- (9CI) (CA INDEX NAME)



RN 327184-19-0 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 9,11-dimethoxy- (9CI) (CA INDEX NAME)



RN 327184-20-3 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 3-[(acetyloxy)methyl]- (9CI)

(CA INDEX NAME)



RN 327184-21-4 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 3-[(acetyloxy)methyl]-9-methoxy- (9CI) (CA INDEX NAME)



RN 327184-22-5 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 2-(2-chloroethyl)- (9CI) (CA INDEX NAME)



RN 327184-33-8 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 11-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 327184-35-0 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 11-hydroxy- (9CI) (CA INDEX NAME)



RN 327184-37-2 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 11-(dimethylamino)-4-methoxy- (9CI) (CA INDEX NAME)



RN 327184-39-4 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthroline-10-carboxylic acid, 7-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 327184-41-8 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthroline-7,9(8H)-dione (9CI) (CA INDEX NAME)



RN 327184-43-0 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 9-chloro-11-(dimethylamino)-(9CI) (CA INDEX NAME)



RN 327184-45-2 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 4-hydroxy-, dihydriodide (9CI) (CA INDEX NAME)



●2 HI

RN 327184-47-4 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 4-chloro- (9CI) (CA INDEX NAME)



RN 327184-49-6 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one, 4-(dimethylamino)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:177139 CAPLUS
DOCUMENT NUMBER: 132:303121
TITLE: Mechanism of action studies of cytotoxic marine alkaloids: ascididemin exhibits thiol-dependent oxidative DNA cleavage
AUTHOR(S): Matsumoto, Sandra S.; Sidford, Mathew H.; Holden, Joseph A.; Barrows, Louis R.; Copp, Brent R.
CORPORATE SOURCE: Departments of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, 84112, USA
SOURCE: Tetrahedron Letters (2000), 41(10), 1667-1670
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The cytotoxic marine alkaloid ascididemin has been shown to be a thiol-dependent DNA cleaving agent. Previous mechanisms of action studies have concluded that DNA and/or the DNA processing enzyme topoisomerase II were the cellular targets for the alkaloid - this is the first direct evidence that a pyridoacridone alkaloid can cause DNA cleavage under physiol. conditions.
IT **266306-76-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(cytotoxic ascididemin exhibits thiol-dependent oxidative DNA cleavage)
RN 266306-76-7 CAPLUS
CN 7H-Pyrido[4,3,2-de][1,7]phenanthrolin-7-one (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	9.49	157.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.30	-1.30

STN INTERNATIONAL LOGOFF AT 15:24:03 ON 09 MAY 2003